Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: A meta-analysis

American Journal of Roentgenology

Volumn 195, Issue 1, 2010, Pages 260-268

  Yuan, Ying ^a   Chen, Xiao Song ^b   Liu, Shi Yuan ^a   Shen, Kun Wei ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast neoplasm; Meta analysis; MRI; Pathological complete remission; Preoperative therapy

Indexed keywords

ADIMYCINE; ANTINEOPLASTIC AGENT; BIS(METHYAMIDE); CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; HUMAN; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77954746388     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.3908     Document Type: Article

References (55)

1. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008; 246:116-124
2. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18:1927-1934
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188-194
4. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102
5. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174
6. Rastogi P, Anderson S, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778-785
7. Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 2008; 19:465-472
8. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Maran HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7:36
9. Goldstein NS, Decker D, Severson D, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007; 110:1687-1696
10. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23:7265-7277
11. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22:2284-2293 (Pubitemid 41115384)
12. Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006; 95:229-233
13. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006; 243:257-264
14. Skaane P, Young K, Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading-Oslo I study. Radiology 2003; 229:877-884
15. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR 2003; 181:1275-1282 (Pubitemid 37296403)
16. Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet 2008; 60:311-334
17. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003; 13:1213-1223
18. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3:25
19. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta- analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31
20. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983-5992
21. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100:552-562
22. Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003; 13:80-87 (Pubitemid 36790494)
23. Chen JH, Mehta RS, Malcioglu O, Su MY. Inflammatory breast cancer following neoadjuvant chemotherapy: can magnetic resonance imaging precisely predict the pathological response? Ann Surg Oncol 2008; 15:3609-3613
24. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112:17-26
25. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11:1115-1124
26. Demartini WB, Lehman CD, Peacock S, Russell MT. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy. Acad Radiol 2005; 12:806-814
27. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001; 8:549-559
28. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002; 72:145-152
29. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR 2002; 179:1193-1199 (Pubitemid 35204372)
30. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neoadjuvant chemotherapy. Eur Radiol 2002; 12:1711-1719
31. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003; 78:51-58
32. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 2003; 228:63-69
33. Bodini M, Berruti A, Bottini A, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 2004; 85:211-218
34. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 2004; 30:1069-1076
35. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14:1371-1379
36. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004; 83:67-76
37. Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 2004; 90:1349-1360
38. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 92:231-238
39. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR 2005; 184:868-877
40. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by threedimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 2006; 12:130-137
41. Belli P, Costantini M, Malaspina C, Magistrelli A, Latoree G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 2006; 61:946-953
42. Garimella V, Qutob O, Fox JN, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 2007; 33:157-161
43. Hsiang DJ, Yamamoto M, Mehta RS, et al. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 2007; 142:855-861
44. Segara D, Krop IE, Garber JE, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007; 96:474-480
45. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breastconserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2008; 98:289-293
46. Nicoletto MO, Nitti D, Pescarini L, et al. Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer. Tumori 2008; 94:481-488
47. Moon HG, Han W, Lee JW, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 2009; 20:636-641
48. Sardanelli F, Giuseppetti GM, Canavese G, et al. Indications for breast magnetic resonance imaging. Consensus document "Attualità in senologia", Florence 2007. Radiol Med 2008; 113:1085-1095
49. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009; 16:1619-1628
50. Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser WA. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 2003; 76:3-12
51. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR 1998; 171:941-949 (Pubitemid 28449949)
52. Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women. J Am Coll Surg 2008; 206:1193-1203
53. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 1997; 75:1318-1323 (Pubitemid 27179822)
54. Kuhl CK, Bieling H, Gieseke J, et al. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. Radiology 1997; 202:87-95 (Pubitemid 27024112)
55. Reichenbach JR, Przetak C, Klinger G, Kaiser WA. Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 1999; 23:407-413